Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 9wald9 who wrote (320)	2/10/2005 12:48:21 PM
From: Jim Oravetz	Read Replies (1) of 370

Vion Agrees With FDA On Phase III Trial Of Cloretazine DOW JONES NEWSWIRES February 10, 2005 9:35 a.m. NEW HAVEN, Conn.-- Vion Pharmaceuticals Inc. (VION) concluded discussions with the Food and Drug Administration on the design of Phase III clinical trials of its lead anticancer agent, Cloretazine, in relapsed acute myelogenous leukemia. In a press release Thursday, the company, which develops agents for the treatment of cancer, said the Food and Drug Administration provided official evaluation and guidance through a special protocol assessment for Cloretazine's trials. The company anticipates starting its trials in the first quarter. They will last about 30 months and will take place in several centers in North America and Europe. Trials will evaluate Cloretazine in combination with Ara-C, cytarabine. Vion posted a loss of $3.9 million, or 7 cents a share, for the fourth quarter, on revenue of $50,000. Vion shares recently traded at $3.28, down 20 cents or 5.7%. In premarket activity, the stock was listed at $3.40. Company Web site: vionpharm.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next